Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer

Agreement Reached to Test Hu5F9-G4 and Avelumab Combo for Ovarian Cancer
A new Phase 1b clinical trial testing a combination treatment of Hu5F9-G4 with avelumab in patients with ovarian cancer is set to begin as part of an agreement between Forty Seven and Merck KGaA, Darmstadt, Germany. "Ovarian cancer patients have limited treatment options, especially as they are often diagnosed at a late stage in their disease," Alise Reicin, head of global clinical development at Merck KGaA, Darmstadt, Germany — which in the U.S. and Canada operates as EMD Serono — said in a press release. "This collaboration enhances our strategic approach to novel [immuno-oncology] combinations in this disease setting. We are hopeful that through these efforts we will discover viable options to help patients with this hard-to-treat cancer." Avelumab is a human programmed death ligand-1 (PD-L1) antibody that blocks PD-L1 interaction with its receptor PD-1, enabling immune system cells known as T-cells to attack cancer cells. The medicine is already approved as Bavencio for metastatic merkel cell carcinoma, an aggressive skin cancer, and metastatic urothelial carcinoma, a form of cancer of the bladder or urinary tra
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *